Management of Alcohol Abuse

Clinics in Liver Disease

Volumn 16, Issue 4, 2012, Pages 737-762

  Albanese, Anthony P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Addiction treatment; Alcohol abuse; Alcohol dependence; Alcohol use disorder; Alcoholism; Detoxification; Recovery; Rehabilitation

Indexed keywords

ACAMPROSATE; ALCOHOL; ARIPIPRAZOLE; BACLOFEN; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CHLORDIAZEPOXIDE; CLONAZEPAM; DIAZEPAM; DISULFIRAM; LORAZEPAM; NALMEFENE; NALTREXONE; ONDANSETRON; OXAZEPAM; PROPOFOL; SEDATIVE AGENT; SERTRALINE; THIAMINE; TOPIRAMATE; VALPROATE SEMISODIUM;

ALCOHOL ABSTINENCE; ALCOHOL ABUSE; ALCOHOL BLOOD LEVEL; ALCOHOL LIVER DISEASE; ALCOHOL METABOLISM; ALCOHOL USE DISORDER; ALCOHOL WITHDRAWAL; ALCOHOLISM; ALTERNATIVE MEDICINE; ANOREXIA; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; COGNITIVE THERAPY; DETOXIFICATION; DRUG ALCOHOL INTERACTION; DRUG EFFICACY; DRUG MEGADOSE; FLUSHING; GASTROINTESTINAL DISEASE; HEADACHE; HEALTH CARE COST; HEALTH INSURANCE; HEMATOLOGIC DISEASE; HUMAN; HYPERACTIVITY; MEDICAL HISTORY; MOTIVATION; NAUSEA AND VOMITING; PARESTHESIA; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SIDE EFFECT; SUPPORT GROUP; TASTE AVERSION; TREATMENT PLANNING; UNITED STATES; UROGENITAL TRACT DISEASE;

ALCOHOLISM; BEHAVIOR THERAPY; COMPLEMENTARY THERAPIES; ETHANOL; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; PREVALENCE; RESIDENTIAL TREATMENT; SELF-HELP GROUPS; UNITED STATES;

EID: 84867940041     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.08.006     Document Type: Review

References (103)

1. Genesis 9:20-1 (RSV).
2. National Institute on Alcohol Abuse and Alcoholism (NIAAA). The physicians' guide to helping patients with alcohol problems (revised). Bethesda, MD: NIAAA; 2004. NIH Publication No. 04-3769.
3. Alcohol and public health. Frequently asked questions. Centers for Disease Control and Prevention Web site. Available at: http://www.cdc.gov/alcohol/faqs.htm.
4. Diagnostic and Statistical Manual of Mental Disorders. Fourth edition. Text revision 2000, American Psychiatric Association, Washington (DC), p. 191-295.
5. Substance abuse and addictive disorders. American Psychiatric Association Web site. Available at: http://www.dsm5.org/proposedrevision/Pages/SubstanceUseandAddictiveDisorders.aspx.
6. Results from the 2010 National Survey on Drug Use and Health: summary of national findings. Available at: http://oas.samhsa.gov/NSDUH/2k10NSDUH/2k10Results.htm.
7. U.S. alcohol epidemiologic data reference manual. National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism Web site. Available at: http://pubs.niaaa.nih.gov/publications/manual.htm.
8. Grant B.F., Stinson F.S., Dawson D.A., et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiological Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004, 61:807-816.
9. Harwood H. Report from Lewin Group for NIAAA 2000 NIH Pub No. 98-4327 from Harwood HJ, Fountain D, Livermore G. Economic cost of alcohol and drug abuse in the United States, 1992: a report. Addiction 1999;94:631-5.
10. Bouchery E.E., Harwood J., Sacks J.J., et al. Economic costs of excessive alcohol consumption in the U.S., 2006. Am J Prev Med 2011, 41(5):546-547.
11. Woodward J.J. The pharmacology of alcohol. ASAM principles of addiction medicine 2003, 101-118. American Society of Addiction Medicine Inc, Chevy Chase (MD). 3rd edition.
12. Cloninger C.R. Neurogenetic adaptive mechanisms in alcoholism. Science 1987, 236:410-416.
13. Dick D.M., Nurnberger J., Edenberg H.J., et al. Suggestive linkage on chromosome 1 for quantitative alcohol-related phenotype. Alcohol Clin Exp Res 2002, 26(10):1453-1460.
14. Dick D.M., Plunkett J., Wetherill L.F., et al. Association between GABRA1 and drinking behaviors in the collaborative study on the genetics of alcoholism sample. Alcohol Clin Exp Res 2006, 30(7):1101-1110.
15. Beresford T.P., Blow F.C., Hill E., et al. Comparison of CAGE questionnaire and computer-assisted laboratory profiles in screening for covert alcoholism. Lancet 1990, 336:482-485.
16. Fiellin D.A., Reid M.C., O'Connor P.G. Outpatient management of patients with alcohol problems. Ann Intern Med 2000, 133:815-827.
17. Bradley K.A., Bush K.R., Epler A.J., et al. Two brief alcohol screening tests from the alcohol use disorders Identification test (AUDIT). Arch Intern Med 2003, 163:821-829.
18. Bradley K., Williams E.C., Achtmeyer C.E., et al. Implementation of evidence-based alcohol screening in the Veterans Health Administration. Am J Manag Care 2006, 12:597-606.
19. Selzer M.L. The Michigan Alcoholism Screening Test: the quest for a new diagnostic instrument. Am J Psychiatry 1971, 127:1653-1658.
20. Pokorny A.D., Miller B.A., Kaplan H.B. The brief MAST: a Shortened version of the Michigan alcoholism screening test. Am J Psychiatry 1972, 129:342-345.
21. Harburg E., Gunn R., Gleiberman L., et al. Using the short Michigan alcoholism screening test to study social drinkers: Tecumseh, Michigan. J Stud Alcohol 1988, 49(6):522-531.
22. Tell D., Nilsson P.M. Early ageing in middle-aged men is associated with adverse social factors and increased mortality risk: the Malmo Preventive Project. Scand J Public Health 2006, 34(4):346-352.
23. Naegle M.A. Screening for alcohol use and misuse in older adults: using the short Michigan alcoholism screening test-geriatric version. Am J Nurs 2008, 108(11):50-58.
24. Schuckit M.A. Alcohol and alcoholism. Harrison's principles of internal Medicine 2012, McGraw-Hill, New York. 18th edition. D.L. Longo, A.S. Fauci, D.L. Kasper (Eds.).
25. Barr C.S., Newman T.K., Becker M.L., et al. Serotonin transporter gene variation is associated with alcohol sensitivity in rhesus macaques exposed to early-life stress. Alcohol Clin Exp Res 2003, 27:812-817.
26. Laucht M., Treutlein J., Schmid B., et al. Impact of psychosocial adversity on alcohol intake in you adults: moderation by the LL genotype of the serotonin transporter polymorphism. Biol Psychiatry 2009, 66:102-109.
27. Koob G.F., Sanna P.P., Bloom F.E. Neuroscience of addiction. Neuron 1998, 21:467-476.
28. Koob G.F., Roberts A.J., Schulteis G., et al. Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res 1998, 22:3-9.
29. Boileau I., Assaad J.M., Pihl R.O., et al. Alcohol promotes dopamine release in the human nucleus accumbens. Synapse 2003, 49:226-231.
30. Ray L.A., Hutchinson K.E. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 2004, 28:1789-1795.
31. Anton R.F., Oroszi G., O'Malley S. An evaluation of mu-opioid receptor (OPRM-1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 2008, 65(2):135-144.
32. Heilig M., Goldman D., Berrettini W., et al. Pharmacogenetic approaches to the treatment of alcohol addiction. Nature 2011, 12:670-684.
33. Liu X., Weiss F. Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotrophin-releasing factor and opioid mechanisms. J Neurosci 2002, 22:7856-7861.
34. Schuckit M.A. Ethanol and methanol. Goodman & Gilman's the pharmacological basis of therapeutics 2011, McGraw-Hill, New York. 12th edition. L.L. Brunton, B.A. Chabner, B.C. Knollmann (Eds.).
35. National Institute for Alcohol Abuse and Alcoholism Alcohol Alerts # 10 & #46 #10 Alcohol and Women. Available at: Are women more vulnerable to alcohol's effects? Available at: Accessed April 30, 2012. http://pubs.niaaa.nih.gov/publications/aa46.htm.
36. Frezza M., di Padova C., Pozzato G., et al. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 1990, 322(2):95.
37. Wurst F.M. Ethyl sulphate: a direct ethanol metabolite reflecting recent alcohol consumption. Addiction 2006, 101(2):204-211.
38. Helander A., Böttcher M., Fehr C., et al. Detection times for urinary ethyl glucuronide and ethyl sulfate in heavy drinkers during alcohol detoxification. Alcohol Alcohol 2009, 44(1):55-61.
39. Varga A., Hansson P., Lundqvist C., et al. Phosphatidylethanol in blood as a marker of ethanol consumption in healthy volunteers: Comparison with other markers. Alcohol Clin Exp Res 1998, 22:1832-1837.
40. Marques P., Tippetts S., Allen J., et al. Estimating driver risk using alcohol biomarkers, interlock BAC tests, and psychometric assessments: initial descriptives. Addiction 2010, 105(2):226-239.
41. ASAM patient placement criteria for the treatment of substance-related disorders, second Edition-revised (ASAM PPC-2R) 2001, 27-33. American Society of Addiction Medicine, Inc, Chevy Chase (MD). D. Mee-Lee, G.D. Shulman, M. Fishman (Eds.).
42. - uptake in cerebral cortical synaptoneurosomes. J Pharmacol Exp Ther 1988, 246:158.
43. Tsai G., Gastfriend D.R., Coyle J.T. The glutamatergic basis of human alcoholism. Am J Psychiatry 1995, 153:332.
44. Korpi E.R., Grunder G., Luddens H. Drug interactions at the GABA(A) preceptors. Prog Neurobiol 2002, 67(2):113-159.
45. Mayo-Smith M.F. Pharmacological management of alcohol withdrawal: a meta-analysis and evidence -based practice guideline. JAMA 1997, 278:144-151.
46. Miller NS, Kipnis SS. Detoxification and substance abuse treatment: a treatment improvement protocol TIP 45. DHHS Publication No SMA08-4131. Rockville (MD): U.S. Department of Health and Human Services; 2006.
47. Malcom R., Myrick H., Brady K.T., et al. Update on anticonvulsants for the treatment of alcohol withdrawal. Am J Addict 2001, 10(Suppl):16-23.
48. Reoux J.P., Saxon A.J., Malte C.A., et al. Divalproex Sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res 2001, 25(9):1324-1329.
49. Eyer F., Schreckenberg M., Hecht D., et al. Carbamazepine and valproate as adjuncts in the treatment of alcohol withdrawal syndrome: a retrospective cohort study. Alcohol Alcohol 2011, 46(2):177-184.
50. Barrons R., Roberts N. The role of carbamazepine and oxcarbazepine in alcohol withdrawal syndrome. J Clin Pharm Ther 2010, 35(2):153-167.
51. Sullivan J.T., Sykora K., Schneiderman J., et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal instrument for alcohol scale (CIWA-Ar). Br J Addict 1989, 84:1353-1357.
52. Saitz R., Mayo-Smith M.F., Roberts M.S., et al. Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial. JAMA 1994, 272:519.
53. Daeppen J.B., Gache P., Landry U., et al. Symptom-triggered vs. fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial. Arch Intern Med 2002, 162:1117.
54. Weaver M.F., Hoffman H.J., Johnson R.E., et al. Alcohol withdrawal pharmacotherapy for inpatients with medical comorbidity. J Addict Dis 2006, 25(2):17-24.
55. Prochaska J.O., DiClemente C.C., Norcross J.C. In search of how people change: applications to the addictive behaviors. Am Psychol 1992, 47:1102-1114.
56. Prochaska J.O. Principles of addiction Medicine 2009, 745-761. American Society of Addiction Medicine, Inc, Chevy Chase (MD). 4th edition. R.K. Ries, D.A. Fiellin, S.C. Miller (Eds.).
57. Leamon M.H., Wright T.M., Myrick H. Substance related disorders. The American psychiatric publishing textbook of psychiatry 2008, 365-406. American Psychiatric Publishing Inc, Arlington (VA). R.E. Hales, S.C. Yudofsky, G.O. Gabbard (Eds.).
58. Miller W.R., Zweben A., Di Clemente C.C., et al. Motivational enhancement therapy Manual 1994, U.S. Dept of Health and Human Services, Rockville (MD).
59. Kadden R., Carroll K.M., Donavan D., et al. Cognitive behavioral coping skills therapy manual 1994, U.S. Dept of Health and Human Services, Rockville (MD).
60. Matching alcoholism treatments to client heterogeneity: project MATCH post treatment drinking outcomes. J Stud Alcohol 1997, 58:7-29. Project MATCH Research Group.
61. Project MATCH secondary a priori hypotheses. Addiction 1997, 92(12):1671-1698. Project MATCH Research Group.
62. Matching alcoholism treatments to client heterogeneity: project MATCH three year drinking outcomes. Alcohol Clin Exp Res 1998, 22(6):1300-1311. Project MATCH Research Group.
63. Helping patients who drink too much: a clinician's guide. National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism Web site. Updated 2005 edition. Available at: http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/clinicians_guide.htm.
64. Incorporating alcohol pharmacotherapies into medical practice: a review of the literature 2009, U.S. Department of Health and Human Services, Rockville (MD).
65. Jorgensen C.H., Pedersen B., Tonnesen H. The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin Exp Res 2011, 35(10):1749-1758.
66. Laaksonen E., Koski-Jannes A., Salspuro M., et al. A randomized, mulitcentre, open-labeled, comparative trial of disulfiram, naltrexone, and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol 2008, 43(1):53-61.
67. Chick J., Gough K., Falkowski W., et al. Disulfiram treatment of alcoholism. Br J Psychiatry 1992, 161:84-89.
68. Pelc I., Verbanck P., Le Bon O., et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: a 90- day placebo-controlled dose-finding study. Br J Psychiatry 1997, 171:73-77.
69. Sass H., Soyka M., Mann K., et al. Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996, 53:673-680.
70. Paille F.M., Guelfi J.D., Perkins A.C., et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995, 30:239-247.
71. Kranzler H.R., Gage A. Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials. Am J Addict 2008, 17(1):70-76.
72. Anton R.F., O'Malley S.S., Ciraulo D.A., et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006, 295:2003-2017.
73. Mason B.J., Goodman A.M., Chabac S., et al. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. Jpn Psychol Res 2006, 40:383-393.
74. Mason B.J. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry 2001, 62(Suppl 10):42-48.
75. Mann K., Lehert P., Morgan M.Y. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004, 28:51-63.
76. Garbutt J.C., West S.L., Carey T.S. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999, 281(14):1318-1325.
77. Witkiewitz K., Saville K., Hamreus K. Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility. Ther Clin Risk Manag 2012, 8:45-53.
78. Volpicelli J.R., Alterman A.I., Hayashida M., et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992, 49:876-880.
79. O'Malley S.S., Jaffe A.J., Chang G., et al. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 1992, 49:881-887.
80. Donovan D.M., Anton R.F., Miller W.R., et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes. J Stud Alcohol Drugs 2008, 69(1):5-13.
81. Volpicelli J.R., Rhines K.C., Rhines J.S., et al. Naltrexone and alcohol dependence: the role of subject compliance. Arch Gen Psychiatry 1997, 54:737-742.
82. Kranzler H.R., Stephenson J.J., Montejano L., et al. Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization. Addiction 2008, 103(11):1801-1808.
83. Vivitrol (naltrexone for extended-release injectable suspension) prescribing information 2010, Alkermes, Inc, Waltham (MA).
84. Garbutt J.C., Kranzler H.R., O'Malley S.S., et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005, 293:1617-1625.
85. Bryson W.C., McConnell J., Korthuis P.T., et al. Extended-release naltrexone for alcohol dependence: persistence and healthcare costs and utilization. Am J Manag Care 2011, 17(Suppl 8):S213-221.
86. Baser O., Chalk M., Rawson R., et al. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence. Am J Manag Care 2011, 17(Suppl 8):S222-234.
87. Lapham S.C., McMillan G.P. Open-label pilot study of extended-release naltrexone to reduce drinking and driving among repeat offenders. J Addict Med 2011, 5(3):163-169.
88. Edwards S., Kenna G.A., Swift R.M., et al. Current and promising pharmacotherapies and novel research target areas in the treatment of alcohol dependence: a review. Curr Pharm Des 2011, 17(14):1323-1332.
89. Johnson B.A. Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs 2005, 19(10):873-896.
90. Johnson B.A., Rosenthal N., Capece J.A., et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007, 298:1641-1651.
91. Rigal L., Anexandre-Dubroeucq C., de Beaurepaire R., et al. Abstinence and "low-risk" consumption 1 year after the initiation of high-dose baclofen: a retrospective study among "high-risk" drinkers. Alcohol Alcohol 2012, 47(4):439-442.
92. Johnson B.A., Ait-Daoud N., Seneviratne C., et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry 2011, 168(3):265-275.
93. Kranzler H.R., Armeli S., Tennen H., et al. A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype. J Clin Psychopharmacol 2011, 31(1):22-30.
94. Kranzler H.R., Armeli S., Tennen H. Post-treatment outcomes in a double-blind, randomized trial of sertraline for alcohol dependence. Alcohol Clin Exp Res 2012, 36(4):739-744.
95. Karhuvaara S., Simojoki K., Virta A., et al. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo controlled multicenter study. Alcohol Clin Exp Res 2007, 31(7):1179-1187.
96. Myrick H., Li X., Randall P.K., et al. The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics. J Clin Psychopharmacol 2010, 30(4):365-372.
97. Nahin R.L., Barnes M.A., Stussman B.J., et al. Costs of complementary and alternative Medicine (CAM) and frequency of visits to CAM Practitioners: United States, 2007. Natl Health Stat Report 2009, 30(18):1-15.
98. Sokhadze T.M., Cannon R.L., Trudeau D.L. EEG Biofeedback as a treatment for substance use disorders: review, rating of efficacy, and recommendations for further research. Appl Psychophysiol Biofeedback 2008, 33(1):1-28.
99. Li J., Zou Y., Ye J.H. Low frequency electroacupuncture selectively decreases voluntarily ethanol intake in rats. Brain Res Bull 2001, 86(5-6):428-434.
100. Overstreet D.H., Cui C.L., Ma Y.Y., et al. Electroacupuncture reduces voluntary alcohol intake in alcohol-preferring rats via an opiate-sensitive mechanism. Neurochem Res 2008, 33(10):2166-2170.
101. Wilson B. Alcoholics anonymous 1976, Alcoholics Anonymous World Services, Inc, New York, p. 59-60. 3rd edition.
102. Baker J. Celebrate Recovery summit material 2012, Saddleback Church, Saddleback (CA).
103. Peele S. Resisting 12-step coercion: how to fight forced participation in AA, NA, or 12-step treatment. 2001. Available at: http://www.morerevealed.com/library/resist.